Clinical Trial: Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06808984) titled 'Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease' on Jan. 24.

Brief Summary: This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MGLL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

Study Start Date: April 15

Study Type: INTERVENTIONAL

Condition: Agitation Alzheimer Disease

Intervention: DRUG: BMS-986368

Specified dose on specified days

DRUG: Placebo

Specified dose on specified days

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Celgene

Disclaimer: Curated...